Fig. 5From: A combined 2-D and 3-D QSAR modeling, molecular docking study, design, and pharmacokinetic profiling of some arylimidamide-azole hybrids as superior L. donovani inhibitorsCorrelation between predicted pIC50 and experimental pIC50 for training and test sets a FFDSEL, b UVEPLSBack to article page